Psychedelic drug makers rally as Trump orders FDA to expedite reviews [Yahoo! Finance]
AtaiBeckley Inc. (ATAI)
US:NASDAQ Investor Relations:
ir.atai.net.cn
Company Research
Source: Yahoo! Finance
President Donald Trump signed an executive ?order directing health regulators to speed up reviews of psychedelic ?drugs and boosted federal research funding. Shares of Atai Life Sciences jumped 21% before the bell, while ?Definium Therapeutics rose 15% and Compass Pathways climbed 26%. GH Research gained 19%, Enveric BioSciences added 7%, and U.S.-listed shares of Cybin were up about 15%. The executive order, issued on Saturday, tells the U.S. Food and Drug Administration to ?fast-track reviews of treatments ?such as ibogaine, a psychedelic compound being studied for mental health conditions including post-traumatic stress disorder, depression and addiction. The order ?directs the agency to give Commissioner's National Priority Vouchers to psychedelic drugs that have the "breakthrough therapy" tag, potentially cutting the review time to 1 to 2 ?months from ?the usual 6 to 10 months. FDA ?Commissioner Marty Makary on Saturday ?said decisions on the drugs could come as soon as t
Show less
Read more
Impact Snapshot
Event Time:
ATAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATAI alerts
High impacting AtaiBeckley Inc. news events
Weekly update
A roundup of the hottest topics
ATAI
News
- Trade Mark Registry Proceedings at the UKIPO Training Course (ONLINE EVENT: May 13, 2026) [Yahoo! Finance]Yahoo! Finance
- AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS DrugsGlobeNewswire
- AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline CatalystGlobeNewswire
- AtaiBeckley: BPL-003 Phase 3 Momentum Keeps Me Bullish [Seeking Alpha]Seeking Alpha
- BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 InitiationGlobeNewswire
ATAI
Earnings
- 11/12/25 - Miss
ATAI
Sec Filings
- 4/10/26 - Form 4
- 3/24/26 - Form 4
- 3/20/26 - Form 144
- ATAI's page on the SEC website